Welcome to The Pharmacogenomics Journal

The Pharmacogenomics Journal is dedicated to the rapid publication of original research on basic pharmacogenomics research and its clinical applications. Publishing six times a year, the journal aims to provide the highest caliber of coverage concerning the effects of genetic variability on drug toxicity and efficacy, the characterization of polymorphisms relevant to drug action, and the identification of novel genomic targets for drug development.


Ranked in the top 10% of Pharmacology & Pharmacy titles*, with an impact factor that continues to rise, and a commitment to speedy online publication, Editor-in-Chief, Julio Licinio, invites you to join our mission of delivering compelling research to the scientific community by submitting your original research to The Pharmacogenomics Journal.


Volume 17, No 3
June 2017

ISSN: 1470-269X
EISSN: 1473-1150

2015 Impact Factor 4.229*
37/254 Pharmacology & Pharmacy
37/167 Genetics & Heredity

Editor:
Julio Licinio, MD

*2015 Journal Citation Reports® Science Edition (Thomson Reuters, 2016)

NEWS

The authors of a recent paper present RH panels as a cost-effective and efficient tool to identify mammalian drug targets at single-gene resolution. Using a human RH panel, the authors identified an important gene for the action of antitubulin drugs that had been overlooked by other strategies.

The results of a recent study published in The Pharmacogenomics Journal provide insight into both unique and shared clinical effects of leukotriene modifiers (LTMs) in treatment of asthma, and represent a potential mechanism for the responsiveness to leukotriene antagonists in asthma patients.

Visit Nature Publishing Group's open access funding page for information about research funders and institutions that provide funding for open access. NPG also offers an APC support service to make it easier for NPG authors to discover and apply for open access funding. For advice on what funding is available to you and help in approaching funders and institutions, please contact us at openaccess@nature.com.

TOP TEN MOST VIEWED PAPERS


The Top Ten charts the articles that have been downloaded most often over the previous 30 days, in HTML and PDF format, from the The Pharmacogenomics Journal website. The chart does not rank the quality, scientific significance or citation impact of the content. However, it may bring articles to your attention that you might not have otherwise noticed. We hope you enjoy them.


May 2017

  1. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

    M Ingelman-Sundberg

    doi:10.1038/sj.tpj.6500285

    Abstract | Full Text | PDF

  2. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders

    J T McCracken, K K Badashova, D J Posey, M G Aman, L Scahill, E Tierney, L E Arnold, B Vitiello, F Whelan, S Z Chuang, M Davies, B Shah, C J McDougle & E L Nurmi

    doi:10.1038/tpj.2013.23

    Abstract | Full Text | PDF

  3. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes

    C Guillemette

    doi:10.1038/sj.tpj.6500171

    Abstract | Full Text | PDF

  4. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy

    S P R Romaine, K M Bailey, A S Hall & A J Balmforth

    doi:10.1038/tpj.2009.54

    Abstract | Full Text | PDF

  5. Ethical, social and legal issues in pharmacogenomics

    D C Wertz

    doi:10.1038/sj.tpj.6500188

    Abstract | Full Text | PDF

  6. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication

    J Kirchheiner, H Schmidt, M Tzvetkov, J-Tha Keulen, J Lötsch, I Roots & J Brockmöller

    doi:10.1038/sj.tpj.6500406

    Abstract | Full Text | PDF

  7. Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput

    X Chen & P F Sullivan

    doi:10.1038/sj.tpj.6500167

    Abstract | Full Text | PDF

  8. Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity

    J J Sutherland, Y W Webster, J A Willy, G H Searfoss, K M Goldstein, A R Irizarry, D G Hall & J L Stevens

    doi:10.1038/tpj.2017.17

    Abstract | Full Text | PDF

  9. The clinical role of genetic polymorphisms in drug-metabolizing enzymes

    D Tomalik-Scharte, A Lazar, U Fuhr & J Kirchheiner

    doi:10.1038/sj.tpj.6500462

    Abstract | Full Text | PDF

  10. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression

    S Fuke, S Suo, N Takahashi, H Koike, N Sasagawa & S Ishiura

    doi:10.1038/sj.tpj.6500026

    Abstract | Full Text | PDF